Recording and classifying MET receptor mutations in cancers

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The MET receptor tyrosine kinase (RTK) is frequently deregulated in various cancers, promoting tumor progression.
• The first MET mutation linked to cancer was identified in hereditary papillary renal cancer (HPRC) in 1997.
• MET mutations, particularly in the kinase domain, often lead to ligand-independent activation.

Purpose of the Study:

• To review the characterization of MET mutations in cancer development.
• To outline the discovery and implications of novel MET mutations, including exon 14 skipping.
• To discuss the challenges in predicting the transforming activity and TKI sensitivity of newly discovered MET mutations.

Main Methods:

• Literature review of MET mutations in cancer.
• Analysis of the impact of MET mutations on receptor activation and cancer progression.
• Review of therapeutic strategies targeting MET, including tyrosine kinase inhibitors (TKIs).

Main Results:

• Tyrosine kinase inhibitors (TKIs) targeting MET are approved for advanced non-small cell lung cancer (NSCLC) with specific MET mutations.
• MET exon 14 skipping mutations, discovered in 2014, represent a distinct class of MET alterations.
• While MET TKIs show efficacy in NSCLC with MET exon 14 skipping, resistance mechanisms involving new MET mutations have emerged.

Conclusions:

• The discovery and characterization of MET mutations have been pivotal in advancing cancer therapy.
• Ongoing research is crucial for understanding novel MET mutations and their response to TKIs.
• Predicting the transforming potential and TKI sensitivity of MET mutations is essential for personalized cancer treatment strategies.